Mi Ra Kim

Title: Mi Ra Kim: Innovator in Cancer Treatment

Introduction

Mi Ra Kim is a notable inventor based in Hwaseong-si, South Korea. She has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. Her innovative work focuses on developing compounds that can effectively combat drug resistance in cancer cells.

Latest Patents

Mi Ra Kim holds a patent for a sulfonamide derivative with a fused pyrimidine skeleton. This compound is known for its epidermal growth factor receptor mutation inhibitory effect. The patent describes a novel fused pyrimidine-based sulfonamide derivative represented by Formula I, along with its solvates and pharmaceutically acceptable salts. The pharmaceutical composition that includes this derivative as an active ingredient has shown promise in suppressing the growth of cancer cells and overcoming drug resistance caused by mutations in the tyrosine kinase domain of epidermal growth factor receptors.

Career Highlights

Mi Ra Kim is currently associated with Hanmi Pharm. Co., Ltd., where she continues her research and development efforts. Her work has been instrumental in advancing cancer therapies and improving patient outcomes. She has a strong focus on innovative solutions that address critical challenges in oncology.

Collaborations

Mi Ra Kim collaborates with talented colleagues, including Sun Young Jang and Ji Young Jeon. Their combined expertise enhances the research and development efforts at Hanmi Pharm. Co., Ltd.

Conclusion

Mi Ra Kim's contributions to cancer treatment through her innovative patent demonstrate her commitment to advancing medical science. Her work not only addresses significant challenges in cancer therapy but also holds the potential to improve the lives of many patients.